Asunto(s)
Antígeno Ki-1/inmunología , Linfoma Cutáneo de Células T/patología , Piel/patología , Biopsia con Aguja , Terapia Combinada , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Extremidad Inferior , Linfoma Cutáneo de Células T/diagnóstico , Linfoma Cutáneo de Células T/terapia , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Medición de Riesgo , Resultado del Tratamiento , Terapia Ultravioleta/métodosRESUMEN
In the last years we have been able to establish CD26 as an operational marker for a human Th1-like reaction in various granulomatous diseases. Recently, CD30 was described as a marker for a Th2-type reaction, where CD30 is preferentially expressed and its soluble form released by human T cell clones producing Th2-type cytokines. To evaluate the possibility of CD30 as an eventual operational marker for a human Th2-like reaction in vivo, we performed immunohistological stainings on frozen sections of skin biopsies from patients with lepromatous and tuberculoid leprosy. A maximum of three to four CD30-positive cells was found per section, and there was no difference in the accumulation of CD30-positive cells between the tuberculoid and the lepromatous form of leprosy. With respect to CD26-positive cells, a high number was found in tuberculoid leprosy in contrast to a greatly reduced expression of CD26 in lepromatous leprosy. We conclude that, while CD26 was confirmed as an operational marker for a Th1-like reaction in leprosy, CD30 does not represent an operational Th2 marker in this disease.